The trial accomplished both equally its Key endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and remarkable improvements in liver fibrosis without having worsening of steatohepatitis, together with resolution of steatohepatitis without worsening of liver fibrosis in people with MASH as compared to placebo.1Assuming the abo